PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer pill tested in 23 patients, study halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
Cancer drug study halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 22, 2026 14:05 UTC